#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

A Polyubiquitin Chain Reaction: Parkin Recruitment to Damaged Mitochondria


article has not abstract


Published in the journal: . PLoS Genet 11(1): e32767. doi:10.1371/journal.pgen.1004952
Category: Perspective
doi: https://doi.org/10.1371/journal.pgen.1004952

Summary

article has not abstract

Mutations in the E3 ubiquitin ligase Parkin or the mitochondrial kinase PINK1 cause autosomal recessive forms of Parkinson’s disease [1, 2]. Genetic and cell biological studies have implicated PINK1 and Parkin as critical elements in mitophagy, a mitochondrial quality control pathway that involves the ubiquitin-proteasome system (UPS) and the autophagy-lysosomal system [1, 2]. Under basal conditions, PINK1 is processed by mitochondrial proteases and targeted for degradation by the UPS [1, 2]. Following persistent mitochondrial damage (e.g., treatment with the mitochondrial uncoupling agent CCCP) PINK1 is stabilized and accumulates in an active form on the outer mitochondrial membrane [1, 2]. Although PINK1 activity is essential for the mitochondrial recruitment of cytoplasmic Parkin and for the subsequent ubiquitin-dependent clearance of damaged mitochondria, the mode of Parkin activation and recruitment has been elusive [1, 2].

A series of recent papers indicates that PINK1 initiates mitophagy by a two-pronged mechanism involving direct phosphorylation of ubiquitin at serine 65 [35] and the ubiquitin-like domain (UbL) of Parkin, also, at serine 65 [68] (Fig. 1A, steps 1–2). Biochemical and structural analyses of Parkin demonstrated that the unique Parkin domain (UPD):Rcat interface (previously termed RING0:RING2), the repressor element of Parkin (REP):RING1 interface, and potentially the UbL:RING1 interface mediate autoinhibition of Parkin under steady state conditions in the cell [914]. It is tempting to speculate that PINK1 phosphorylation of the Parkin UbL and/or the binding of phosphorylated ubiquitin releases the autoinhibitory elements to allow E2~Ub binding or facilitates conformational rearrangements to confer E2~Ub discharge, ultimately leading to exposure of an optimally aligned Parkin active site. Although the studies on PINK1 phosphorylation of ubiquitin [35] and Parkin [68] suggest a novel mechanism for PINK1 activation of Parkin, the expression of phosphomimetics of ubiquitin and Parkin was insufficient to promote the mitochondrial recruitment of Parkin [3, 8]. Thus the mechanism underlying PINK1-mediated Parkin recruitment remained a mystery.

Fig. 1. Damage-induced feedforward and positive feedback loops mediate the cellular decision to destroy mitochondria.
Damage-induced feedforward and positive feedback loops mediate the cellular decision to destroy mitochondria.
(A) In healthy cells the mitochondrial kinase PINK1 is proteolytically processed and degraded by the UPS. Following mitochondrial damage, PINK1 is stabilized and phosphorylates ubiquitin and the Parkin UbL (step 1), activating Parkin and promoting the polyubiquitination of mitochondrial outer membrane substrates (step 2). The polyubiquitin chains are then phosphorylated by PINK1 (step 3) and mediate the recruitment of additional Parkin to the mitochondria (step 4). (B) Network motifs in the PINK1-Parkin pathway. Mitochondrial damage inhibits PINK1 degradation, initiating dual coherent feedforward loops in the activation of Parkin and generation of phosphorylated polyubiquitin and a positive feedback loop in Parkin recruitment. (C) Hypothetical graph modeling the relationship between mitochondrial damage signal persistence (brief—blue line, and persistent—red line) and the accumulation of phosphorylated polyubiquitin chains during the progression towards mitophagy commitment. UPS, ubiquitin-proteasome system.

In December’s issue of PLOS Genetics, Shiba-Fukushima et al. provide compelling data indicating that PINK1 directly phosphorylates polyubiquitin chains to mediate the mitochondrial recruitment and activation of Parkin (Fig. 1A, steps 3–4) [15]. In vitro, affinity purified Parkin from cells bound purified polyubiquitin chains phosphorylated by recombinant PINK1 with a preference for long K63-linked polyubiquitin over K48-linked polyubiquitin chains, although this preference was not recapitulated with Parkin purified from bacteria. To simulate mitochondrial linked polyubiquitin chains, the authors expressed four tandem copies of ubiquitin G76V fused to the mitochondrial targeting sequence of Tom70 [15]. Phosphomimetic (S65E) versions of the tandem polyubiquitin chains were bound by Parkin through its RING1-BRcat domains (previously termed RING1:IBR) and were able to promote stable mitochondrial association of Parkin even in the absence of mitochondrial damage [15]. Both cytosolic phosphomimetic ubiquitin and mitochondrially targeted phosphomimetic tandem polyubiquitin chains were sufficient to activate Parkin, as evidenced by increased Parkin C431S-ubiquitin oxyester formation, but only when the Parkin UbL phosphomimetic was used [15]. To further understand the physiological importance of their findings, Shiba-Fukushima et al. employed PINK1-/- and Parkin -/- Drosophila models, which are associated with severe mitochondrial swelling and matrix disorganization and age-dependent motor defects. Strikingly, the expression of mitochondrially targeted phosphomimetic tandem polyubiquitin chains significantly improve both mitochondrial morphology and motor function in PINK1-/- flies, with little effect on mitochondrial morphology in Parkin -/- flies [15]. These results are in excellent agreement with a recent publication that employed quantitative proteomics to study PINK1-stimulated Parkin polyubiquitination [16]. Together, these two publications [15, 16] suggest that PINK1 phosphorylation of polyubiquitin is the rate-limiting event required for the mitochondrial recruitment, and potentially also the activation, of Parkin.

The destruction of mitochondria represents an irreversible cellular decision with significant consequences for cellular physiology. The emerging data support a model in which the decision to degrade damaged mitochondria is controlled by dual coherent feedforward loops that precede a positive feedback loop (Fig. 1B). In a feedfoward loop, two input factors, one of which controls the other, jointly regulate a third target factor. In the PINK1-Parkin pathway, the first feedforward loop mediates maximal activation of Parkin by PINK1 phosphorylation of the Parkin UbL and of ubiquitin. The second feedforward loop involves the generation of mitochondrial polyubiquitin chains by PINK1-activated Parkin, and/or another mitochondrial E3 ligase, and their subsequent phosphorylation by PINK1. These phosphorylated polyubiquitin chains appear to be capable of initiating a self-propagating positive feedback loop, recruiting Parkin to the mitochondria and presumably stimulating polyubiquitination of mitochondrial substrates, which can then be phosphorylated by PINK1 and recruit additional Parkin. The organization of these network motifs predicts beneficial features with respect to the decision to degrade mitochondria, including an initial delay period and a mechanism to detect the persistence of mitochondrial damage (Fig. 1C). During the delay period (i.e., low levels of phosphorylated polyubiquitin), the decision to commit to mitophagy would be rapidly reversible, providing a useful means of filtering out brief, low levels of mitochondrial damage signals and preventing unwarranted mitochondrial destruction (Fig. 1C, blue line). Only a persistent damage stimulus that overcomes a specific threshold would be sufficient to initiate the positive feedback loop and commit mitochondria for mitophagy (Fig. 1C, red line). The actions of putative unidentified ubiquitin and Parkin UbL phosphatases, or of mitochondrial deubiquitinating enzymes USP30 [17], USP15 [18], or USP8 [19], which antagonize Parkin-mediated polyubiquitination, would be predicted to regulate the extent of the delay period and the precise commitment threshold. Interestingly, USP30 has been reported to be targeted for UPS degradation by Parkin [17], providing an elegant mechanism to gradually reduce the magnitude of UPS30’s influence during persistent mitochondrial damage.

The new study from Shiba-Fukushima et al. [15] contributes an intriguing model for the role of PINK1 in Parkin recruitment to damaged mitochondria and raises several interesting questions for future investigation. Is an unidentified Parkin UbL and/or ubiquitin phosphatase involved in mitochondrial quality control? The mitochondrial phosphatase PGAM5, which functions downstream of PINK1 [20], is a logical candidate. If polyubiquitination induces the proteasomal degradation of tagged substrates, how does the phospho-polyubiquitin mitochondrial signal persist, are they shielded by phospho-polyubiquitin binding domain-containing proteins or not efficiently recognized by the proteasome? Does Parkin self-association [21] amplify the feedforward loop? How is the binding and exchange of substrates, phospho-polyubiquitin chains and/or phospho-ubiquitin by Parkin coordinated to control the timing of substrate degradation? Finally, it will be imperative to determine the therapeutic potential of small molecule mimetics of phosphorylated ubiquitin (or Parkin UbL) and regulators of the PINK1-Parkin mitochondrial quality control pathway in the search for cures of idiopathic Parkinson’s disease.


Zdroje

1. Narendra D, Walker JE, Youle R (2012) Mitochondrial quality control mediated by PINK1 and Parkin: links to parkinsonism. Cold Spring Harb Perspect Biol 4: a011338. doi: 10.1101/cshperspect.a011338 23125018

2. Winklhofer KF (2014) Parkin and mitochondrial quality control: toward assembling the puzzle. Trends Cell Biol 24: 332–341. doi: 10.1016/j.tcb.2014.01.001 24485851

3. Koyano F, Okatsu K, Kosako H, Tamura Y, Go E, et al. (2014) Ubiquitin is phosphorylated by PINK1 to activate parkin. Nature 510: 162–166. 24784582

4. Kazlauskaite A, Kondapalli C, Gourlay R, Campbell DG, Ritorto MS, et al. (2014) Parkin is activated by PINK1-dependent phosphorylation of ubiquitin at Ser65. Biochem J 460: 127–139. doi: 10.1042/BJ20140334 24660806

5. Kane LA, Lazarou M, Fogel AI, Li Y, Yamano K, et al. (2014) PINK1 phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity. J Cell Biol 205: 143–153. doi: 10.1083/jcb.201402104 24751536

6. Iguchi M, Kujuro Y, Okatsu K, Koyano F, Kosako H, et al. (2013) Parkin-catalyzed ubiquitin-ester transfer is triggered by PINK1-dependent phosphorylation. J Biol Chem 288: 22019–22032. doi: 10.1074/jbc.M113.467530 23754282

7. Kondapalli C, Kazlauskaite A, Zhang N, Woodroof HI, Campbell DG, et al. (2012) PINK1 is activated by mitochondrial membrane potential depolarization and stimulates Parkin E3 ligase activity by phosphorylating Serine 65. Open Biol 2: 120080. doi: 10.1098/rsob.120080 22724072

8. Shiba-Fukushima K, Imai Y, Yoshida S, Ishihama Y, Kanao T, et al. (2012) PINK1-mediated phosphorylation of the Parkin ubiquitin-like domain primes mitochondrial translocation of Parkin and regulates mitophagy. Sci Rep 2: 1002. doi: 10.1038/srep01002 23256036

9. Chaugule VK, Burchell L, Barber KR, Sidhu A, Leslie SJ, et al. (2011) Autoregulation of Parkin activity through its ubiquitin-like domain. EMBO J 30: 2853–2867. doi: 10.1038/emboj.2011.204 21694720

10. Riley BE, Lougheed JC, Callaway K, Velasquez M, Brecht E, et al. (2013) Structure and function of Parkin E3 ubiquitin ligase reveals aspects of RING and HECT ligases. Nat Commun 4: 1982. doi: 10.1038/ncomms2982 23770887

11. Spratt DE, Martinez-Torres RJ, Noh YJ, Mercier P, Manczyk N, et al. (2013) A molecular explanation for the recessive nature of parkin-linked Parkinson's disease. Nat Commun 4: 1983. doi: 10.1038/ncomms2983 23770917

12. Spratt DE, Walden H, Shaw GS (2014) RBR E3 ubiquitin ligases: new structures, new insights, new questions. Biochem J 458: 421–437. doi: 10.1042/BJ20140006 24576094

13. Trempe JF, Sauve V, Grenier K, Seirafi M, Tang MY, et al. (2013) Structure of parkin reveals mechanisms for ubiquitin ligase activation. Science 340: 1451–1455. doi: 10.1126/science.1237908 23661642

14. Wauer T, Komander D (2013) Structure of the human Parkin ligase domain in an autoinhibited state. EMBO J 32: 2099–2112. doi: 10.1038/emboj.2013.125 23727886

15. Shiba-Fukushima K, Arano T, Matsumoto G, Inoshita T, Yoshida S, et al. (2014) Phosphorylation of Mitochondrial Polyubiquitin by PINK1 Promotes Parkin Mitochondrial Tethering. PLoS Genet 10: e1004861. doi: 10.1371/journal.pgen.1004861 25474007

16. Ordureau A, Sarraf SA, Duda DM, Heo JM, Jedrychowski MP, et al. (2014) Quantitative Proteomics Reveal a Feedforward Mechanism for Mitochondrial PARKIN Translocation and Ubiquitin Chain Synthesis. Mol Cell 56: 360–375. doi: 10.1016/j.molcel.2014.09.007 25284222

17. Bingol B, Tea JS, Phu L, Reichelt M, Bakalarski CE, et al. (2014) The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy. Nature 510: 370–375. 24896179

18. Cornelissen T, Haddad D, Wauters F, Van Humbeeck C, Mandemakers W, et al. (2014) The deubiquitinase USP15 antagonizes Parkin-mediated mitochondrial ubiquitination and mitophagy. Hum Mol Genet 23: 5227–5242. doi: 10.1093/hmg/ddu244 24852371

19. Durcan TM, Tang MY, Perusse JR, Dashti EA, Aguileta MA, et al. (2014) USP8 regulates mitophagy by removing K6-linked ubiquitin conjugates from parkin. EMBO J 33: 2473–2491. doi: 10.15252/embj.201489729 25216678

20. Imai Y, Kanao T, Sawada T, Kobayashi Y, Moriwaki Y, et al. (2010) The loss of PGAM5 suppresses the mitochondrial degeneration caused by inactivation of PINK1 in Drosophila. PLoS Genet 6: e1001229. doi: 10.1371/journal.pgen.1001229 21151955

21. Lazarou M, Narendra DP, Jin SM, Tekle E, Banerjee S, et al. (2013) PINK1 drives Parkin self-association and HECT-like E3 activity upstream of mitochondrial binding. J Cell Biol 200: 163–172. doi: 10.1083/jcb.201210111 23319602

Štítky
Genetika Reprodukční medicína

Článek vyšel v časopise

PLOS Genetics


2015 Číslo 1
Nejčtenější tento týden
Nejčtenější v tomto čísle
Kurzy

Zvyšte si kvalifikaci online z pohodlí domova

Důležitost adherence při depresivním onemocnění
nový kurz
Autoři: MUDr. Eliška Bartečková, Ph.D.

Koncepce osteologické péče pro gynekology a praktické lékaře
Autoři: MUDr. František Šenk

Sekvenční léčba schizofrenie
Autoři: MUDr. Jana Hořínková, Ph.D.

Hypertenze a hypercholesterolémie – synergický efekt léčby
Autoři: prof. MUDr. Hana Rosolová, DrSc.

Multidisciplinární zkušenosti u pacientů s diabetem
Autoři: Prof. MUDr. Martin Haluzík, DrSc., prof. MUDr. Vojtěch Melenovský, CSc., prof. MUDr. Vladimír Tesař, DrSc.

Všechny kurzy
Přihlášení
Zapomenuté heslo

Zadejte e-mailovou adresu, se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se

#ADS_BOTTOM_SCRIPTS#